Table 3.

Treatment-related adverse events occurring at any grade or at grade ≥3 in ≥2 patients in either group

	ICI-naïve (n=18)		ICI-experienced (n=23)
	Any grade, n (%)	Grade ≥3, n (%)	Any grade, n (%)	Grade ≥3, n (%)
Any TRAEs	14 (77.8)	6 (33.3)	17 (73.9)	1 (4.3)
Keratoacanthoma	3 (16.7)	0	3 (13.0)	0
Rash maculopapular	3 (16.7)	1 (5.6)	2 (8.7)	0
Pruritus	3 (16.7)	0	2 (8.7)	0
Dyspnea	2 (11.1)	1 (5.6)	0	0
Infusion-related reaction	2 (11.1)	1 (5.6)	0	0
Fatigue	2 (11.1)	0	2 (8.7)	0
Decreased appetite	2 (11.1)	0	3 (13.0)	0
Diarrhea	1 (5.6)	0	2 (8.7)	0
Nausea	1 (5.6)	0	2 (8.7)	0
Rash	1 (5.6)	0	2 (8.7)	0
Vomiting	1 (5.6)	0	2 (8.7)	0
Asthenia	0	0	2 (8.7)	0

ICI, immune checkpoint inhibitor; TRAEs, treatment-related adverse events.